icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3: the VALENCE Trial
 
 
  Reported by Jules Levin
Presented at The Liver Meeting® 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases, November 1-5, 2013, Washington, DC
 
Stefan Zeuzem,1 Geoffrey M. Dusheiko,2 Riina Salupere,3 Alessandra Mangia,4 Robert Flisiak,5 Robert H. Hyland,6 Ari Illeperuma,6 Evguenia S. Svarovskaia,6 Diana M. Brainard,6 William T. Symonds,6 John G. McHutchison,6 Ola Weiland,7 Hendrik W. Reesink,8 Peter Ferenci,9 Christophe Hézode,10 Rafael Esteban11 1Johann Wolfgang Goethe University, Frankfurt, Germany; 2Royal Free and University College School of Medicine, Royal Free Hospital, London, United Kingdom; 3Tartu University Hospital, Tartu, Estonia; 4Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 5Medical University of Bialystok, Poland;
6Gilead Sciences, Inc., Foster City, CA; 7Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden; 8Academic Medical Center, Amsterdam, the Netherlands; 9Medical University of Vienna, Austria; 10Centre Hospitalier Universitaire Henri Mondor de Créteil, France; 11Hospital Universitario Vall d'Hebron, Barcelona, Spain

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif